ArticleCancer cell international2026
From bioinformatics to bedside: PPBP drives glioblastoma progression under hypoxia via CXCR2/PI3K/Akt signaling and is targetable by Oenothein B.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlioblastoma multiforme (GBM) is an aggressive brain cancer closely linked to hypoxic conditions and altered lactate metabolism. This study aims to investigate the prognostic factors of GBM by developing models that integrating hypoxia and lactate metabolism, and to leverage bioinformatics techniques to gain deeper insights in this process.
methodsPublicly available GBM datasets identified hypoxia-lactate metabolism-related prognostic genes. Bioinformatics analyses included differential expression, functional enrichment, consensus clustering, immune profiling, and prognostic risk modeling. PPBP expression was validated via ELISA, Western blot, and RT-qPCR. Functional effects of PPBP knockdown/overexpression were assessed using CCK-8, EdU, wound healing, and Transwell assays under normoxia/hypoxia. Molecular mechanisms were explored with ChIP, dual-luciferase reporter, Co-IP, and pathway inhibition assays. Xenograft models evaluated in vivo tumor growth and survival. Virtual screening and SPR identified PPBP-targeting compounds, validated pharmacologically in vitro and in vivo.
resultsIntegrated bioinformatics and experimental research identified 165 hypoxia-lactate metabolism-related genes in GBM. A seven-gene prognostic signature was established, with PPBP validated as a key hypoxia-induced oncogene. PPBP knockdown suppressed malignant phenotypes and glycolysis under hypoxia via CXCR2/PI3K/AKT signaling. HIF-1α transcriptionally activated PPBP through direct promoter binding. The natural compound Oenothein B targeted PPBP, inhibiting tumor growth and lactate metabolism in vitro and in vivo.
conclusionThis research develops a hypoxia-lactate metabolism-related gene signature to predict GBM prognosis, identifies PPBP as a key driver of hypoxic tumor progression via HIF-1α transcription and CXCR2/PI3K/AKT signaling, and shows that the natural compound Oenothein B targets PPBP to suppress glioma growth, offering a potential GBM therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.